RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $4.00 Average PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has received an average rating of "Hold" from the nine analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.00.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 10th.

Hedge Funds Weigh In On RAPT Therapeutics

Several large investors have recently modified their holdings of RAPT. Medicxi Ventures Management Jersey Ltd acquired a new position in RAPT Therapeutics in the 4th quarter valued at about $35,316,000. TCG Crossover Management LLC bought a new stake in shares of RAPT Therapeutics during the fourth quarter worth approximately $19,751,000. Orbimed Advisors LLC acquired a new position in shares of RAPT Therapeutics in the fourth quarter valued at approximately $20,754,000. Foresite Capital Management VI LLC acquired a new stake in RAPT Therapeutics during the 4th quarter worth approximately $19,750,000. Finally, RTW Investments LP bought a new stake in RAPT Therapeutics in the 4th quarter valued at $18,587,000. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Stock Performance

RAPT stock traded down $0.01 during midday trading on Monday, hitting $0.79. 781,946 shares of the company's stock were exchanged, compared to its average volume of 1,271,099. The stock's fifty day moving average price is $1.13 and its 200-day moving average price is $1.37. RAPT Therapeutics has a one year low of $0.75 and a one year high of $8.58. The company has a market cap of $104.35 million, a PE ratio of -0.29 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). On average, analysts expect that RAPT Therapeutics will post -2.14 EPS for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.